查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2024773

體內CRO市場報告：按類型、GLP類型、適應症和地區分類（2026-2034年）

In-vivo CRO Market Report by Type (Rodent, Non-Rodent), GLP Type (Non-GLP, GLP Toxicology), Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, and Others), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球體內CRO市場規模達57億美元。預計到2034年，該市場規模將達到101億美元，2026年至2034年的複合年成長率為6.49%。全球慢性病盛行率的上升以及製藥公司研發投入的增加是推動市場成長的主要因素。

體內CRO市場趨勢：

製藥公司外包業務增加

為了提高研發效率並降低成本，製藥公司正致力於將體內試驗外包給合約研究組織（CRO）。這些CRO提供動物試驗方面的專業知識，能夠加速藥物開發和監管核准流程，使公司能夠專注於其核心業務。例如，2024年7月，為數據驅動型商業化提供綜合數據、諮詢、技術和外包平台的IntegriChain收購了領先的醫藥諮詢和管理服務公司Federal Compliance Solutions (FCS)，旨在建立更具盈利的藥物商業化策略。根據一份體內試驗CRO市場分析報告，這是推動市場成長的主要因素。

專業CRO服務的興起

專業體內CRO服務的興起反映了臨床前試驗領域對特定專業知識日益成長的需求。這些CRO在動物模型、藥物動力學和毒理學等領域提供客製化服務，提高了治療藥物研發的效率和準確性，並擴大了體內CRO市場的需求。例如，2024年6月，Lindus Health推出了一體化的醫療設備CRO服務，該服務整合了體內CRO專業知識、先進技術和受試者招募策略。這簡化了醫療設備的臨床試驗流程，並加快了各個治療領域和監管途徑的受試者招募。

人們越來越關注藥物研發

隨著藥物研發的日益受到重視，對體內CRO（合約研究組織）的支持也不斷擴大。這些機構為臨床前試驗提供至關重要的服務，使製藥公司能夠在活體生物體內評估新藥的安全性和有效性，從而加快研發進程，同時降低成本和資源需求。例如，Cannovation Clinical Research Partners於2024年5月成立，是專注於大麻素藥物臨床試驗的CRO。該公司專注於臨床前和臨床階段，透過與製藥公司、大學和美國緝毒局（DEA）研究人員的合作，推動大麻素療法的研發。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球體內CRO市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 囓齒動物
    • 主要部分
      • 鼠
      • 老鼠
      • 其他
  • 不囓齒類動物

第7章 市場區隔：依GLP類型分類

  • 非GLP規範
    • 主要部分
      • 內部
      • 外包
  • GLP毒性測試
    • 主要部分
      • 內部
      • 外包

第8章 市場區隔：依適應症分類

  • 自體免疫/發炎性疾病
    • 主要部分
      • 類風濕性關節炎
      • 多發性硬化症
      • 骨關節炎
      • 大腸激躁症
      • 其他
  • 疼痛管理
    • 主要部分
      • 慢性疼痛
      • 急性疼痛
  • 腫瘤學
    • 主要部分
      • 血癌
      • 固體癌
      • 其他
  • 中樞神經系統疾病
    • 主要部分
      • 癲癇
      • 帕金森氏症
      • 亨丁頓舞蹈症
      • 中風
      • 創傷性腦損傷
      • ALS
      • 肌肉再生
      • 其他
  • 糖尿病
  • 肥胖
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Biocytogen
    • Charles River Laboratories
    • Crown Bioscience
    • Eurofins Discovery
    • Evotec
    • Fortrea
    • Icon Plc
    • IQVIA Inc.
    • Iris Pharma
    • Taconic Biosciences, Inc.
    • WuXi AppTec
Product Code: SR112026A6267

The global in-vivo CRO market size reached USD 5.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 10.1 Billion by 2034, exhibiting a growth rate (CAGR) of 6.49% during 2026-2034. The growing prevalence of chronic diseases worldwide and the increasing R&D expenditure by pharmaceutical companies are propelling the market growth.

IN-VIVO CRO MARKET ANALYSIS:

  • Major Market Drivers: The rapid growth in the number of biotech startups and the rising focus on personalized and precision medicine are stimulating the market growth.
  • Key Market Trends: Various outsourcing preclinical research studies and the inflating adoption of artificial intelligence in research methodologies are acting as growth-inducing factors.
  • Competitive Landscape: Some of the prominent market companies include Biocytogen, Charles River Laboratories, Crown Bioscience, Eurofins Discovery, Evotec, Fortrea, Icon Plc, IQVIA Inc., Iris Pharma, Taconic Biosciences, Inc., and WuXi AppTec, among many others.
  • Geographical Trends: North America dominates the market due to due to advanced healthcare infrastructure, strong pharmaceutical and biotechnology sectors, and high R&D investment.
  • Challenges and Opportunities: The high costs and regulatory challenges hinder the market growth. However, adopting advanced technologies and streamlining compliance processes to enhance efficiency and reduce expenses will continue to propel the market growth over the foreseeable future.

IN-VIVO CRO MARKET TRENDS:

Increased Outsourcing by Pharmaceutical Companies

Pharmaceutical companies are focusing on outsourcing to in-vivo contract research organizations to enhance research efficiency and reduce costs. These CROs provide specialized expertise in animal studies, thereby enabling faster drug development and regulatory approval while allowing companies to focus on core competencies. For example, in July 2024, IntegriChain, delivering pharma's comprehensive data, consulting, technology, and outsourcing platform for data-driven commercialization, acquired Federal Compliance Solutions (FCS), a leading pharma advisory and managed services firm, to develop more profitable drug commercialization strategies. According to the in-vivo CRO market analysis report, this is acting as a growth-inducing factor.

Rise of Specialized CRO Services

The rise of specialized in-vivo CRO services reflects a growing demand for niche expertise in preclinical studies. These CROs offer tailored services in areas like animal modeling, pharmacokinetics, and toxicology, enhancing drug development efficiency and precision in therapeutic research and development, escalating the in-vivo CRO market demand. For instance, in June 2024, Lindus Health launched an all-in-one medical device CRO service, combining in-vivo CRO expertise with advanced technology and recruitment strategies, streamlining medical device clinical trials, accelerating participant enrollment across various therapeutic areas and regulatory pathways, etc.

Growing Focus on Drug Development

The increasing emphasis on drug development has led to greater support for in-vivo CRO. These organizations provide essential services for preclinical testing, enabling pharmaceutical companies to evaluate the safety and efficacy of new drugs in living organisms, speeding up the development process while reducing costs and resource requirements. For example, in May 2024, Cannovation Clinical Research Partners launched as a CRO specializing in cannabis-based drug trials, focusing on preclinical and clinical phases, developed cannabinoid-based therapeutics through collaborations with pharmaceutical companies, universities, and DEA researchers.

GLOBAL IN-VIVO CRO INDUSTRY SEGMENTATION:

Breakup by Type:

  • Rodent
    • Rats
    • Mice
    • Others
  • Non-Rodent

Rodent dominates the in-vivo CRO market share

Rodents, particularly mice and rats, dominate the market due to their genetic similarity to humans, cost-effectiveness, and rapid breeding. For example, mice are extensively used for cancer research and drug testing in preclinical trials. Moreover, companies, such as Envigo and Charles River Laboratories, developed advanced rodent models and enhanced services to support several stages of drug development.

Breakup by GLP Type:

  • Non-GLP
    • In House
    • Outsourcing
  • GLP Toxicology
    • In House
    • Outsourcing

GLP toxicology exhibits a clear dominance in the market

According to the in-vivo CRO market forecast report, GLP toxicology dominates the market, as companies strive to meet the growing demand for rigorous safety assessment in drug development. Advanced GLP toxicology services, including innovative study designs, specialized toxicology models, and enhanced data analytics platforms by leading organizations, like Covance and Labcorp Drug Development, are gaining traction.

Breakup by Indication:

  • Autoimmune/Inflammation Conditions
    • Rheumatoid Arthritis
    • Multiple Sclerosis
    • Osteoarthritis
    • Irritable Bowel Syndrome
    • Others
  • Pain Management
    • Chronic Pain
    • Acute Pain
  • Oncology
    • Blood Cancer
    • Solid Tumor
    • Others
  • CNS Conditions
    • Epilepsy
    • Parkinson's Disease
    • Huntington's Disease
    • Stroke
    • Traumatic Brain Injury
    • ALS
    • Muscle Regeneration
    • Others
  • Diabetes
  • Obesity

Oncology dominates the in-vivo CRO market outlook

Oncology dominates the market due to the high demand for cancer drug research and development. For example, CROs conduct animal studies to evaluate the efficacy and safety of new oncology therapies before clinical trials. Besides this, the rising innovations in supporting biotech and pharmaceutical companies to develop new cancer therapies are driving the segment's growth.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America dominates the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

According to the in-vivo CRO market outlook report, North America leads the market due to its advanced healthcare infrastructure, substantial R&D investment, and presence of major pharmaceutical companies. The region benefits from a strong regulatory framework, experienced researchers, and high clinical trial activity. For instance, Charles River Laboratories, a key player in the U.S., provides comprehensive in-vivo services, from early-stage research to preclinical testing, which attracts global clients seeking high-quality, reliable research outcomes. This advantage positions North America as a dominant region.

COMPETITIVE LANDSCAPE:

The in-vivo CRO market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • Biocytogen
  • Charles River Laboratories
  • Crown Bioscience
  • Eurofins Discovery
  • Evotec
  • Fortrea
  • Icon Plc
  • IQVIA Inc.
  • Iris Pharma
  • Taconic Biosciences, Inc.
  • WuXi AppTec

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global In-vivo CRO Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Rodent
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Rats
      • 6.1.2.2 Mice
      • 6.1.2.3 Others
    • 6.1.3 Market Forecast
  • 6.2 Non-Rodent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by GLP Type

  • 7.1 Non-GLP
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 In House
      • 7.1.2.2 Outsourcing
    • 7.1.3 Market Forecast
  • 7.2 GLP Toxicology
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 In House
      • 7.2.2.2 Outsourcing
    • 7.2.3 Market Forecast

8 Market Breakup by Indication

  • 8.1 Autoimmune/Inflammation Conditions
    • 8.1.1 Market Trends
    • 8.1.2 Key Segments
      • 8.1.2.1 Rheumatoid Arthritis
      • 8.1.2.2 Multiple Sclerosis
      • 8.1.2.3 Osteoarthritis
      • 8.1.2.4 Irritable Bowel Syndrome
      • 8.1.2.5 Others
    • 8.1.3 Market Forecast
  • 8.2 Pain Management
    • 8.2.1 Market Trends
    • 8.2.2 Key Segments
      • 8.2.2.1 Chronic Pain
      • 8.2.2.2 Acute Pain
    • 8.2.3 Market Forecast
  • 8.3 Oncology
    • 8.3.1 Market Trends
    • 8.3.2 Key Segments
      • 8.3.2.1 Blood Cancer
      • 8.3.2.2 Solid Tumor
      • 8.3.2.3 Others
    • 8.3.3 Market Forecast
  • 8.4 CNS Conditions
    • 8.4.1 Market Trends
    • 8.4.2 Key Segments
      • 8.4.2.1 Epilepsy
      • 8.4.2.2 Parkinson's Disease
      • 8.4.2.3 Huntington's Disease
      • 8.4.2.4 Stroke
      • 8.4.2.5 Traumatic Brain Injury
      • 8.4.2.6 ALS
      • 8.4.2.7 Muscle Regeneration
      • 8.4.2.8 Others
    • 8.4.3 Market Forecast
  • 8.5 Diabetes
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Obesity
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocytogen
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Charles River Laboratories
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Crown Bioscience
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eurofins Discovery
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Evotec
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Fortrea
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Icon Plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 IQVIA Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Iris Pharma
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Taconic Biosciences, Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 WuXi AppTec
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials

List of Figures

  • Figure 1: Global: In-vivo CRO Market: Major Drivers and Challenges
  • Figure 2: Global: In-vivo CRO Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: In-vivo CRO Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: In-vivo CRO Market: Breakup by Type (in %), 2025
  • Figure 5: Global: In-vivo CRO Market: Breakup by GLP Type (in %), 2025
  • Figure 6: Global: In-vivo CRO Market: Breakup by Indication (in %), 2025
  • Figure 7: Global: In-vivo CRO Market: Breakup by Region (in %), 2025
  • Figure 8: Global: In-vivo CRO (Rodent) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: In-vivo CRO (Rodent) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: In-vivo CRO (Non-Rodent) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: In-vivo CRO (Non-Rodent) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: In-vivo CRO (Non-GLP) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: In-vivo CRO (Non-GLP) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: In-vivo CRO (GLP Toxicology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: In-vivo CRO (GLP Toxicology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: In-vivo CRO (Pain Management) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: In-vivo CRO (Pain Management) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: In-vivo CRO (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: In-vivo CRO (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: In-vivo CRO (CNS Conditions) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: In-vivo CRO (CNS Conditions) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: In-vivo CRO (Diabetes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: In-vivo CRO (Diabetes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: In-vivo CRO (Obesity) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: In-vivo CRO (Obesity) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: In-vivo CRO (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: In-vivo CRO (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: North America: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: North America: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: United States: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: United States: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Canada: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Canada: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Asia-Pacific: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Asia-Pacific: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: China: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: China: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Japan: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Japan: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: India: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: India: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: South Korea: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: South Korea: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Australia: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Australia: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Indonesia: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Indonesia: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Others: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Others: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Europe: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Europe: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Germany: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Germany: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: France: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: France: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: United Kingdom: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: United Kingdom: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Italy: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Italy: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Spain: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Spain: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Russia: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Russia: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Others: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Others: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Latin America: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Latin America: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Brazil: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Brazil: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Mexico: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Mexico: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Others: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Others: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Middle East and Africa: In-vivo CRO Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Middle East and Africa: In-vivo CRO Market: Breakup by Country (in %), 2025
  • Figure 78: Middle East and Africa: In-vivo CRO Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Global: In-vivo CRO Industry: SWOT Analysis
  • Figure 80: Global: In-vivo CRO Industry: Value Chain Analysis
  • Figure 81: Global: In-vivo CRO Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: In-vivo CRO Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: In-vivo CRO Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: In-vivo CRO Market Forecast: Breakup by GLP Type (in Million USD), 2026-2034
  • Table 4: Global: In-vivo CRO Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 5: Global: In-vivo CRO Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: In-vivo CRO Market: Competitive Structure
  • Table 7: Global: In-vivo CRO Market: Key Players